APA

Vitale F. V., Romeo P., Vasta F., Panebianco V., Calì S., Rotondo S., Ferraù F. & La Greca M. (20080212). Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. : Anticancer research.

Chicago

Vitale Felice Vito, Romeo Placido, Vasta Fabio, Panebianco Vincenzo, Calì Stefania, Rotondo Stefano, Ferraù Francesco and La Greca Michele. 20080212. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. : Anticancer research.

Harvard

Vitale F. V., Romeo P., Vasta F., Panebianco V., Calì S., Rotondo S., Ferraù F. and La Greca M. (20080212). Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. : Anticancer research.

MLA

Vitale Felice Vito, Romeo Placido, Vasta Fabio, Panebianco Vincenzo, Calì Stefania, Rotondo Stefano, Ferraù Francesco and La Greca Michele. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. : Anticancer research. 20080212.